Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S are described.
Compounds of formula (I),
or pharmaceutically acceptable derivatives thereof, wherein:
R
1
represents a group selected from H, CF
3
, and C
1-6
alkyl (optionally substituted by C
1-6
alkyloxy or triazolyl);
R
2
represents halo;
Ring A represents a 5- or 6-membered heterocyclic ring containing at least one N atom (the ring being optionally bridged with two or more carbon atoms);
R
3
represents a 5- or 6-membered heterocyclic ring containing at least one atom selected from N, O or S, the heterocyclic ring being optionally substituted by one or more groups selected from C
1-6
alkyl oxo or NH
2
, the heterocyclic ring being further optionally fused to a 5- or 6-membered aryl or heterocyclic ring containing at least one atom selected from N, O or S, the fused aryl or heterocyclic ring being substituted by one or more halo atoms;
are useful for treating a disorder for which a V1a antagonist is indicated, in particular, dysmenorrhea.
Substituted pyrazoles and methods of treatment with substituted pyrazoles
申请人:Butler R. Christopher
公开号:US20070117785A1
公开(公告)日:2007-05-24
Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases or allergic conditions, including atopic allergic conditions, mediated by cathepsin S are described.